• By ICR Secretariat
  • Posted Friday, July 8, 2022

5 FDA decisions to watch in the third quarter

https://www.biopharmadive.com/news/5-fda-approval-decisions-third-quarter-2022/625983/

So far in 2022, the Food and Drug Administration’s main review office has approved 16 new medicines. The agency has recently cleared between 45 to 50 treatments each year, so the second half of the year could be busy if historical trends hold.